Aficamten - CAS# 2364554-48-1 Catalog No.:M33502-2 Synthesis of conformationally constrained analogues

Synthesis of conformationally constrained analogues of KN62

3)36-24(35)30-19(15-17-9-5-4-6-10-17)22(34)31-14-8-12-20(31)21(33)29-18(16-32)11-7-13-28-23(26)27

InChi: InChI=1S/C28H24N4O3/c33-25-19-26(28-29-31-32-30-28)35-27-22(10-6-11-24(25)27)15-12-21-13-16-23(17-14-21)34-18-5-4-9-20-7-2-1-3-8-20/h1-3

Isocryptotanshinone inhibits the constitutive STAT3 and p-STAT3 (Y705) expression in concentration and time-dependent manners

Aficamten - CAS# 2364554-48-1 Catalog No.:M33502-2 Synthesis of conformationally constrained analoguesAficamten, CAS No. 2364554 48 1, also known as CK 3773274 and CK 274, is a Next Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy. Aficamten was designed to provide a predicted human half life (t1 2) appropriate for once a day (qd) dosing, to reach steady state within two weeks, to have no substantial cytochrome P450 induction or inhibition, and to have a wide therapeutic window in vivo with a clear pharmacokinetic